Background: A plant based approach was undertaken to ascertain the efficacy of the Technology/Innovation of a new medical Technology based on similar activity to the circulatory system of plants. Basic Technology form...Background: A plant based approach was undertaken to ascertain the efficacy of the Technology/Innovation of a new medical Technology based on similar activity to the circulatory system of plants. Basic Technology formulations were introduced into plant structures to evaluate the responses for cell division and plant growth which ultimately lead to the final product. This Technology/Innovation transforms and enhances common botanical/herb products such that they can be used to treat COVID-19 infection and Serious or Life-threatening conditions or diseases. They can restore the diseased cell’s abnormal metabolism to homeostasis and return it to normal function by slowing or reversing the cell’s malfunctioning metabolism, or in other words, slowing or reversing the disease process. Methods: A systematic treatment for COVID-19 infection and Serious or Life-threatening illness in patients is based on theories of traditional Chinese medicine. The Technology/Innovation is developed as dietary supplement products for treatment of Serious or Life-threatening conditions or diseases. Results: The results consist of over one hundred Serious or Life-threatening patient medical records. The U.S. Food and Drug Administration (FDA) reviewed/evaluated/accepted the Technology/Innovation patient medical record results, which included fifty-four COVID-19 patients with Prioritized Review Expedited No.: 2020-2867 CR2020-2596 information on September 16, 2020 and twenty-seven cancer patients Cancer Survival Rate Results in (Table 1) with FDA Establishment Identification No.: 3012327979 information on March 25, 2019 as FDA-Regulated medical products and meet the requirement under FDA Significant Scientific Agreement standards.展开更多
To understand the effects of Lactobacillus rhamnosus GG(ATCC 53103)on intestinal barrier function in pre-weaning piglets under normal conditions,twenty-four newborn littermate piglets were randomly divided into two gr...To understand the effects of Lactobacillus rhamnosus GG(ATCC 53103)on intestinal barrier function in pre-weaning piglets under normal conditions,twenty-four newborn littermate piglets were randomly divided into two groups.Piglets in the control group were orally administered with 2 mL 0.1 g/mL sterilized skim milk while the treatment group was administered the same volume of sterilized skim milk with the addition of viable L.rhamnosus at the 1st,3rd,and 5th days after birth.The feeding trial was conducted for 25 d.Results showed that piglets in the L.rhamnosus group exhibited increased weaning weight and average daily weight gain,whereas diarrhea incidence was decreased.The bacterial abundance and composition of cecal contents,especially Firmicutes,Bacteroidetes,and Fusobacteria,were altered by probiotic treatment.In addition,L.rhamnosus increased the jejunal permeability and promoted the immunologic barrier through regulating antimicrobial peptides,cytokines,and chemokines via Toll-like receptors.Our findings indicate that oral administration of L.rhamnosus GG to newborn piglets is beneficial for intestinal health of pre-weaning piglets by improving the biological,physical,and immunologic barriers of intestinal mucosa.展开更多
文摘Background: A plant based approach was undertaken to ascertain the efficacy of the Technology/Innovation of a new medical Technology based on similar activity to the circulatory system of plants. Basic Technology formulations were introduced into plant structures to evaluate the responses for cell division and plant growth which ultimately lead to the final product. This Technology/Innovation transforms and enhances common botanical/herb products such that they can be used to treat COVID-19 infection and Serious or Life-threatening conditions or diseases. They can restore the diseased cell’s abnormal metabolism to homeostasis and return it to normal function by slowing or reversing the cell’s malfunctioning metabolism, or in other words, slowing or reversing the disease process. Methods: A systematic treatment for COVID-19 infection and Serious or Life-threatening illness in patients is based on theories of traditional Chinese medicine. The Technology/Innovation is developed as dietary supplement products for treatment of Serious or Life-threatening conditions or diseases. Results: The results consist of over one hundred Serious or Life-threatening patient medical records. The U.S. Food and Drug Administration (FDA) reviewed/evaluated/accepted the Technology/Innovation patient medical record results, which included fifty-four COVID-19 patients with Prioritized Review Expedited No.: 2020-2867 CR2020-2596 information on September 16, 2020 and twenty-seven cancer patients Cancer Survival Rate Results in (Table 1) with FDA Establishment Identification No.: 3012327979 information on March 25, 2019 as FDA-Regulated medical products and meet the requirement under FDA Significant Scientific Agreement standards.
基金Project supported by the National Natural Science Foundation of China (No. 31472128)the Special Research Fund for the PhD Program of University, China (No. 20110101110101)the Key Project of Science and Technology of Zhejiang Province, China (No. 2006C12086)
文摘To understand the effects of Lactobacillus rhamnosus GG(ATCC 53103)on intestinal barrier function in pre-weaning piglets under normal conditions,twenty-four newborn littermate piglets were randomly divided into two groups.Piglets in the control group were orally administered with 2 mL 0.1 g/mL sterilized skim milk while the treatment group was administered the same volume of sterilized skim milk with the addition of viable L.rhamnosus at the 1st,3rd,and 5th days after birth.The feeding trial was conducted for 25 d.Results showed that piglets in the L.rhamnosus group exhibited increased weaning weight and average daily weight gain,whereas diarrhea incidence was decreased.The bacterial abundance and composition of cecal contents,especially Firmicutes,Bacteroidetes,and Fusobacteria,were altered by probiotic treatment.In addition,L.rhamnosus increased the jejunal permeability and promoted the immunologic barrier through regulating antimicrobial peptides,cytokines,and chemokines via Toll-like receptors.Our findings indicate that oral administration of L.rhamnosus GG to newborn piglets is beneficial for intestinal health of pre-weaning piglets by improving the biological,physical,and immunologic barriers of intestinal mucosa.
